General Obstetrics and Gynecology: GynecologyDouble-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception
Section snippets
Material and methods
The study population was drawn from 4 general adolescent health clinics that are located in a large, metropolitan setting between May 2000 and December 2002. Adolescent girls, who ranged in age from 12 to 18 years, who were seeking contraception, and who selected DMPA for their method of contraception were eligible for enrollment. Exclusion criteria included the use of DMPA, pregnancy or abortion over the past 6 months, the use of oral contraceptives over the past 3 months, a chronic medical
Results
At baseline, the study population comprised 123 adolescent girls who selected DMPA as their contraceptive method; 65 girls were assigned randomly to the DMPA-estrogen (DMPA-E) group, and 58 girls were assigned randomly to the DMPA-placebo (DMPA-P) group. In December 2003, the Data Safety Monitoring Board supervised interim analysis of the trial with the recommendation that, if our spine BMD findings at 12 months were significantly different between the 2 treatment groups at a probability value
Comment
In this randomized clinical trial, we found that adolescents who were receiving DMPA-E had significantly higher BMD at both the lumbar spine and femoral neck at 12 and 24 months compared with that seen in girls who were receiving DMPA-P. When the data were adjusted for volumetric changes in bone size, the findings followed a similar pattern at the lumbar spine at 12 and 24 months and the femoral neck at 24 months. The only other randomized controlled clinical trial of estrogen supplementation
Acknowledgments
We thank the following team members for their exceptional efforts: Kelly Camlin-Shingler, MSSA, Ray Harvey, BS, Mary Jo Day, LPN, Darlene Lewis, RN, Rachel Whitsel, BA.
References (22)
- et al.
A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives
J Pediatr
(1996) - et al.
Bone mineral density in a cohort of adolescent women using depot medroxyprogesterone acetate for one to two years
J Adolesc Health
(2003) - et al.
Bone mineral density in adolescent females using depot medroxyprogesterone acetate
J Pediatr Adolesc Gynecol
(2004) - et al.
Comparison of continuation rates for hormonal contraception among adolescents
J Pediatr Adolesc Gynecol
(1999) - et al.
Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception
Fertil Steril
(2001) Current concepts regarding use of DMPA
J Reprod Med
(2002)- et al.
Implants and injectables: recent developments
The Contraception Report
(2000) - et al.
Trends in contraceptive use in the United States: 1982-1995
Fam Plann Perspect
(1998) Census 2000 summary file 1
(2000)- et al.
Bone mineral density in women receiving depot medroxyprogesterone acetate for contraception
BMJ
(1991)
Bone mineral density in women using depot medroxyprogesterone acetate for contraception
Obstet Gynecol
Cited by (69)
Reproductive and hormonal factors and the risk for osteoporosis
2020, Marcus and Feldman’s OsteoporosisFertility, Contraception, and Novel Reproductive Technologies in Chronic Kidney Disease
2017, Seminars in NephrologyBone Mineral Density and Weight Changes in Adolescents Randomized to 3 Doses of Depot Medroxyprogesterone Acetate
2017, Journal of Pediatric and Adolescent GynecologyCanadian Contraception Consensus (part 3 of 4): Chapter 8 - Progestin-only contraception
2016, Journal of Obstetrics and Gynaecology CanadaCitation Excerpt :En raison du manque d’essais comparatifs randomisés ayant utilisé les fractures à titre de critère d’évaluation principal157,166, il est difficile de formuler des conclusions solides au sujet de l’effet de l’utilisation d’AMPR sur les risques de fractures. D’autres facteurs pourraient exercer une influence sur les taux de DMO et ces facteurs sont rarement pris en considération dans les études dont nous disposons au sujet de la relation entre l’utilisation d’AMPR et les risques de fracture / la baisse de la DMO129–131,133,167–171. L’âge avancé, la race / l’ethnicité (Afro-Américaine), la présence d’un IMC élevé, le gain pondéral, les antécédents de grossesse, l’apport en calcium et l’œstrogénothérapie supplémentaire sont tous des facteurs qui pourraient être associés à une hausse de la DMO, tandis qu’un apport élevé en caféine et le tabagisme pourraient être associés à une baisse de la DMO chez les femmes qui utilisent de l’AMPR.
Canadian Contraception Consensus (Part 3 of 4): Chapter 8 - Progestin-Only Contraception
2016, Journal of Obstetrics and Gynaecology CanadaCitation Excerpt :Due to a lack of RCTs using fractures as a primary endpoint,157,166 it is difficult to make a strong conclusion about the effect of DMPA use on the risk of fractures. Other factors may influence BMD levels and rarely are taken into account in available studies on fracture risk and BMD reduction with DMPA use.129–131,133,167–171 Older chronologic age, race/ethnicity (African-American), high BMI, weight gain, history of pregnancy, calcium intake, and additional estrogen therapy may be associated with increased BMD, whereas heavy caffeine intake and smoking may be associated with decreased BMD in women using DMPA.
Premenopausal Reproductive and Hormonal Characteristics and the Risk for Osteoporosis
2013, Osteoporosis: Fourth Edition
Supported by National Institutes of Health grant R01HD39009 and General Clinical Research Center grant M1RR00080I2.